5-Hydroxydecanoate sodium是一种选择性的ATP敏感性钾（KATP）通道阻滞剂，IC50值为28.7μM。
Cas No.:71186-53-3
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
5-Hydroxydecanoate sodium is a selective ATP-sensitive K+ (KATP) channel blocker with an IC50 value of 28.7μM [1]. 5-Hydroxydecanoate sodium can traverse the mitochondrial inner membrane and acts as a substrate for mitochondrial outer membrane acyl-CoA synthetase, with the activity of inhibiting both ischaemic and pharmacological preconditioning [2]. 5-Hydroxydecanoate sodium has been widely used to alter mitochondrial membrane potential and inhibit the proliferation of hypoxic human pulmonary artery smooth muscle cells (hPASMCs)[3].
In vitro, 5-Hydroxydecanoate sodium treatment (10μM) for 24 hours inhibited the toxicity of 6-hydroxydopamine (6-OHDA) to isolated dopaminergic neurons and blocked the decrease in mitochondrial membrane potential induced by 6-OHDA[4]. Pre-treatment with 100μM 5-Hydroxydecanoate sodium for 30 minutes significantly abolished the inhibitory effect of Penehyclidine hydrochloride (PHC) on the cell damage in H9c2 cells induced by anoxia/reoxygenation (A/R), promoted Ca2+ overload and ROS generation, and facilitated the release of cytochrome C from mitochondria into the cytoplasm[5]. Treatment with 100μM 5-Hydroxydecanoate sodium for 20 minutes can weaken the protective effect of puerarin (Pue) in the isolated cardiomyocyte ischemia model and promote cell death[6].
In vivo, injecting 5-Hydroxydecanoate sodium (10mg/kg) and paclitaxel (4.5mg/kg) intraperitoneally every other day for a week enabled the mice to regain the thermal sensitivity and alleviate mechanical allodynia[7]. Two intraperitoneal injections of 5-Hydroxydecanoate sodium (5mg/kg) were administered weekly for 12 weeks, which aggravated the atherosclerotic degree and pro-inflammatory response in ApoE−/− mice fed with a high-fat diet[8].
References:
[1] Li X, Rapedius M, Baukrowitz T, et al. 5-Hydroxydecanoate and coenzyme A are inhibitors of native sarcolemmal KATP channels in inside-out patches[J]. Biochimica et Biophysica Acta (BBA)-General Subjects, 2010, 1800(3): 385-391.
[2] Hanley P J, Gopalan K V, Lareau R A, et al. β‐Oxidation of 5‐hydroxydecanoate, a Putative Blocker of Mitochondrial ATP‐Sensitive Potassium Channels[J]. The Journal of physiology, 2003, 547(2): 387-393.
[3] Wang T, ZHANG Z, XU Y, et al. 5‐Hydroxydecanoate inhibits proliferation of hypoxic human pulmonary artery smooth muscle cells by blocking mitochondrial KATP channels 1[J]. Acta Pharmacologica Sinica, 2007, 28(10): 1531-1540.
[4] Rodriguez-Pallares J, Parga J A, Joglar B, et al. The mitochondrial ATP-sensitive potassium channel blocker 5-hydroxydecanoate inhibits toxicity of 6-hydroxydopamine on dopaminergic neurons[J]. Neurotoxicity research, 2009, 15(1): 82-95.
[5] Zi C, Zhang C, Yang Y, et al. Penehyclidine hydrochloride protects against anoxia/reoxygenation injury in cardiomyocytes through ATP‐sensitive potassium channels, and the Akt/GSK‐3β and Akt/mTOR signaling pathways[J]. Cell Biology International, 2020, 44(6): 1353-1362.
[6] Gao Q, Pan H Y, Qiu S, et al. Atractyloside and 5-hydroxydecanoate block the protective effect of puerarin in isolated rat heart[J]. Life sciences, 2006, 79(3): 217-224.
[7] Chen L H, Sun Y T, Chen Y F, et al. Integrating image-based high-content screening with mouse models identifies 5-hydroxydecanoate as a neuroprotective drug for paclitaxel-induced neuropathy[J]. Molecular cancer therapeutics, 2015, 14(10): 2206-2214.
[8] Zhang Y, Ding X, Yuan C, et al. Anti-Inflammatory Responses Produced with Nippostrongylus brasiliensis-Derived Uridine via the Mitochondrial ATP-Sensitive Potassium Channel and Its Anti-Atherosclerosis Effect in an Apolipoprotein E Gene Knockout Mouse Model[J]. Biomolecules, 2024, 14(6): 672.
5-Hydroxydecanoate sodium是一种选择性的ATP敏感性钾（KATP）通道阻滞剂，IC50值为28.7μM[1]。5-Hydroxydecanoate sodium可穿过线粒体内膜，作为线粒体外膜酰辅酶A合成酶的底物，具有抑制缺血性和药理性预适应的活性[2]。5-Hydroxydecanoate sodium已被广泛用于改变线粒体膜电位并抑制缺氧状态下人肺动脉平滑肌细胞(hPASMCs)的增殖[3]。
在体外，使用10μM的5-Hydroxydecanoate sodium处理24小时，抑制了6-羟基多巴胺（6-OHDA）对分离的多巴胺能神经元的毒性，并阻断了6-OHDA诱导的线粒体膜电位下降[4]。用100μM的5-Hydroxydecanoate sodium预处理30分钟，显著消除了Penehyclidine hydrochloride (PHC)对缺氧/复氧（A/R）诱导的H9c2细胞损伤的抑制作用，促进了Ca2+超载和ROS生成，并促进了细胞色素C从线粒体释放到细胞质[5]。使用100μM的5-Hydroxydecanoate sodium处理20分钟，可削弱puerarin (Pue)在离体心肌细胞缺血模型中的保护作用，并促进细胞死亡 [4]。
在体内，每隔一天腹腔注射5-Hydroxydecanoate sodium（10mg/kg）和紫杉醇（4.5mg/kg），持续一周，使小鼠恢复了热敏感性并减轻了机械性痛觉超敏[7]。每周两次腹腔注射5-Hydroxydecanoate sodium（5mg/kg），持续12周，加剧了高脂饮食喂养的ApoE−/−小鼠的动脉粥样硬化程度和促炎反应[8]。
| Cell experiment [1]: | |
Cell lines | H9c2 cells |
Preparation Method | H9c2 cells were maintained in Dulbecco's Modified Eagle Medium (DMEM) containing 10% fetal bovine serum (FBS) in a humidified 5% CO2 incubator (95% air/5% CO2) at 37°C. H9c2 cells were seeded at 4×105 cells per well in six-well plates and cultured at 37°C before dividing into 5 groups. (i) Control group: H9c2 cells were cultured in Tyrode solution for 3h and then in DMEM for another 2h in a humidified 5% CO2 incubator (95% air/5% CO2) at 37°C. (ii) PHC group: H9c2 cells were pretreated with 0.1μM PHC and then processed as the control group. (iii) A/R group: H9c2 cells were cultured in an anoxic atmosphere (95% N2/5% CO2) for 3h and then re-oxygenated (95% air/5% CO2) for another 2h. (iv) A/R + PHC group: H9c2 cells were pretreated with 0.1μM PHC for 2h prior to A/R treatment. (v) A/R+PHC+5-Hydroxydecanoate sodium group: H9c2 cells were pretreated with 100μM 5-Hydroxydecanoate sodium for 30min and then with 0.1μM PHC for another 2h prior to A/R treatment. Cell proliferation was determined. |
Reaction Conditions | 100μM; 24h |
Applications | 5-Hydroxydecanoate sodium treatment abolished the inhibitory effect of PHC on the cell death in H9c2 cells induced by A/R. |
| Animal experiment [2]: | |
Animal models | Female C57BL/6J mice |
Preparation Method | Female C57BL/6J mice (ages 7 weeks) were housed in a temperature-controlled (23±2°C) room maintained on a 12/12h light/dark cycle. Paclitaxel (4.5mg/kg), vehicle (saline), or 5-Hydroxydecanoate sodium (10mg/kg) was injected intraperitoneally on four alternative days (days 0, 2, 4, and 6). The baseline measurement of each test was taken prior to paclitaxel or vehicle administration, and five additional sessions of tests were recorded weekly for 5 weeks. Heat hypersensitivity of tail withdrawal was measured by the tail immersion assay. Motor function impairment was measured by the grip strength test. |
Dosage form | 10mg/kg; every other day for a week; i.p. |
Applications | 5-Hydroxydecanoate sodium treatment enabled the mice to regain the thermal sensitivity and alleviate mechanical allodynia. |
References: | |
| Cas No. | 71186-53-3 | SDF | |
| 别名 | 5-羟基癸酸钠盐 | ||
| Canonical SMILES | CCCCCC(O)CCCC(O[Na])=O | ||
| 分子式 | C10H19NaO3 | 分子量 | 210.25 |
| 溶解度 | DMSO : 12.5 mg/mL (59.45 mM; Need ultrasonic); H2O : 10 mg/mL (47.56 mM; Need ultrasonic) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 4.7562 mL | 23.7812 mL | 47.5624 mL |
| 5 mM | 951.2 μL | 4.7562 mL | 9.5125 mL |
| 10 mM | 475.6 μL | 2.3781 mL | 4.7562 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet